Operating as a biotechnology company in the US, DiObex focuses on developing groundbreaking products for the treatment of various metabolic disorders such as type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Their product lineup includes DIO-901, an ultra-low dose glucagon solution designed to reduce nocturnal hypoglycemia in type-one diabetes patients, and DIO-902, a cortisol synthesis inhibitor aimed at managing glucose and cholesterol levels in type-two diabetes patients. Founded in 2003 and headquartered in San Francisco, California, DiObex is committed to advancing the field of metabolic disorder treatment.